uniQure N.V. (NasdaqGS: QURE)
Health Care · Biotechnology · NL
$22.54
-2.59% today · -62.4% 1Y
uniQure N.V. (NasdaqGS: QURE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.56B and employs 221 people.
Over the last twelve months the share price has lost 62.4%, trading between 8.73 and 71.50.
Tweenvest scores uniQure N.V. across four factors: quality 34/100, value 54/100, growth 0/100. Its strongest factor is value.
QURE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.56B
- Revenue (TTM)
- $18.67M
- P/E
- —
- EPS
- -4.04
- Dividend yield
- —
- Beta (5Y)
- 1.06
- 52-week high
- $71.50
- 52-week low
- $8.73
- Avg volume (3M)
- —
- Shares outstanding
- 69.37M
- Employees
- 221
- Next earnings
- —
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
- ISIN
- NL0010696654
- Founded
- 1998
- Listed since
- Feb 5, 2014
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| InventisBio Co., LimitedSHSE: 688382 | $1.65B | CN¥19.07 | +1.71% |
| COMPASS Pathways plcNasdaqGS: CMPS | $1.59B | $11.47 | -1.88% |
| Yantai Dongcheng Pharmaceutical Group Co.,Ltd.SZSE: 002675 | $1.59B | CN¥12.90 | +1.74% |
| Syndax Pharmaceuticals, Inc.NasdaqGS: SNDX | $1.57B | $16.90 | -3.98% |
| Wedge Industrial Co.,Ltd.SZSE: 000534 | $1.56B | CN¥21.63 | -4.46% |
| Stoke Therapeutics, Inc.NasdaqGS: STOK | $1.55B | $23.95 | -1.40% |
| Absci CorporationNasdaqGS: ABSI | $1.53B | $8.94 | -3.04% |
| GenFleet Therapeutics (Shanghai) Inc.SEHK: 2595 | $1.51B | HK$31.94 | +6.82% |
Figures last refreshed Oct 4, 2026.